Zeaxanthin: study protocols
11 study groups say how much Zeaxanthin participants took a day. These are the doses the studies gave. They are not a recommendation.
Dose per serving from products
1,586 products in our catalogue print how much Zeaxanthin a serving holds.
Most common: 1 mg to 2.5 mg, 31% of 1,586 products.
| Dose per serving | Products |
|---|---|
| 50 mcg or less | 40 |
| 50 mcg to 100 mcg | 63 |
| 100 mcg to 250 mcg | 73 |
| 250 mcg to 500 mcg | 166 |
| 500 mcg to 1 mg | 263 |
| 1 mg to 2.5 mg | 487 |
| 2.5 mg to 5 mg | 362 |
| 5 mg to 10 mg | 78 |
| over 10 mg | 54 |
Dose per serving from research
11 study groups in 6 studies say how much Zeaxanthin participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 mg to 2.5 mg, 55% of 11 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mcg or less | 1 |
| 100 mcg to 250 mcg | 1 |
| 250 mcg to 500 mcg | 0 |
| 500 mcg to 1 mg | 1 |
| 1 mg to 2.5 mg | 6 |
| 2.5 mg to 5 mg | 0 |
| 5 mg to 10 mg | 2 |
Commonly used together
9 of 11 study groups took Zeaxanthin with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Lutein | 9 |
| Omega-3 Fatty Acids | 3 |
11 study groups
| Study | |||
|---|---|---|---|
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · lutein + zeaxanthin group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 2 mg | 5 years | — |
| Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 2014 · lutein/zeaxanthin · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified | 2 mg | 1789 days | — |
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 2 mg | 5 years | — |
| Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 2014 · lutein/zeaxanthin and DHA/EPA · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified | 2 mg | 1789 days | — |
| Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration 2015 · lutein (10 mg) + zeaxanthin (10 mg) · Adults aged over 50 with clinically diagnosed early age-related macular degeneration | 10 mg | 2 years | 28 |
| Plasma kinetics of zeaxanthin and 3'-dehydro-lutein after multiple oral doses of synthetic zeaxanthin 2004 · 1 mg zeaxanthin group · Healthy adult volunteers; age and sex not specified | 1 mg | 6 weeks | — |
| Plasma kinetics of zeaxanthin and 3'-dehydro-lutein after multiple oral doses of synthetic zeaxanthin 2004 · 10 mg zeaxanthin group · Healthy adult volunteers; age and sex not specified | 10 mg | 6 weeks | — |
| Lutein supplementation increases breast milk and plasma lutein concentrations in lactating women and infant plasma concentrations but does not affect other carotenoids 2014 · low-dose group · Women aged 18 years or older, 4–6 weeks postpartum, continuously lactating and breastfeeding full-term singleton infants | 96 mcg | 6 weeks | 29 |
| Lutein supplementation increases breast milk and plasma lutein concentrations in lactating women and infant plasma concentrations but does not affect other carotenoids 2014 · high-dose group · Women aged 18 years or older, 4–6 weeks postpartum, continuously lactating and breastfeeding full-term singleton infants | 192 mcg | 6 weeks | 26 |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 lutein plus zeaxanthin · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye | 2 mg | 5 years | — |